Diagnosis and Treatment of Cancer Cachexia
Pfizer External Research & Grants (ER&G) (formerly Global Medical Grants & Partnerships) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s ER&G competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: March 24, 2026
Geographic Scope: United States, United Kingdom, France, Spain, Germany, Italy, and Japan are the priority countries although proposals with global reach are also encouraged
Clinical Area: Cancer cachexia
Link to full RFP: Diagnosis and Treatment of Cancer Cachexia
Application Due Date: May 14, 2026
Specific Area of Interest:
This RFP is seeking proposals for independent education initiatives that will improve the ability of healthcare professionals to:
- Recognize the signs and symptoms of cachexia.
- Use diagnostic tools to assess, measure and correctly document cachexia in patient records.
- Utilize current strategies to improve appetite, lean body mass, or physical function in patients with cachexia.
- Understand the mechanism of GDF-15 and its role as a target in cachexia treatment.
- Be aware of, and consider patients for cachexia clinical trials, understanding the status of new therapeutic options currently in development.
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.